9 Meters Biopharma’s celiac disease drug isn’t measuring up in a phase 3 trial. After an interim analysis found that the study needs an enrollment count that is too large to support continuation, the company is scouring data on sub-groups to see if the therapy may have a treatment effect.
Larazotide Acetate News Full Screen View
Market Place
Share